Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trial for use in women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease. It is also developing NBI-74788, which is in Phase II clinical trial that is used for the treatment of congenital adrenal hyperplasia. In addition, the company's research programs comprise VMAT2 Inhibitors for movement disorders, bipolar disorders, and schizophrenia; and G Protein-Coupled Receptors and Ion Channels for epilepsy, essential tremor, pain, dystonia, and other indications. It has collaborations and agreements with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women's and men's health; Mitsubishi Tanabe Pharma Corporation to develop and commercialize INGREZZA for movement disorders; and BIAL ? Portela & Ca, S.A. to develop and commercialize opicapone for the treatment of human diseases and conditions, including Parkinson's disease. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:NBIX
CUSIP64125C10
Phone858-617-7600
Debt
Debt-to-Equity Ratio1.03
Current Ratio11.06
Quick Ratio11.06
Price-To-Earnings
Trailing P/E Ratio-61.44
Forward P/E Ratio-471.76
P/E GrowthN/A
Sales & Book Value
Annual Sales$161.63 million
Price / Sales55.10
Cash FlowN/A
Price / CashN/A
Book Value$4.21 per share
Price / Book23.53
Profitability
EPS (Most Recent Fiscal Year)($1.62)
Net Income$-142,540,000.00
Net Margins-45.56%
Return on Equity-29.67%
Return on Assets-13.46%
Miscellaneous
Employees400
Outstanding Shares89,900,000
Neurocrine Biosciences (NASDAQ:NBIX) Frequently Asked Questions
What is Neurocrine Biosciences' stock symbol?
Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."
How were Neurocrine Biosciences' earnings last quarter?
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) released its earnings results on Monday, April, 30th. The company reported ($0.47) EPS for the quarter, missing analysts' consensus estimates of ($0.29) by $0.18. The company earned $71.08 million during the quarter, compared to analyst estimates of $65.17 million. Neurocrine Biosciences had a negative return on equity of 29.67% and a negative net margin of 45.56%. During the same quarter last year, the business earned ($0.90) earnings per share. View Neurocrine Biosciences' Earnings History.
When is Neurocrine Biosciences' next earnings date?
What price target have analysts set for NBIX?
13 analysts have issued 12 month price objectives for Neurocrine Biosciences' stock. Their forecasts range from $79.00 to $120.00. On average, they expect Neurocrine Biosciences' stock price to reach $102.7692 in the next year. View Analyst Ratings for Neurocrine Biosciences.
Who are some of Neurocrine Biosciences' key competitors?
Some companies that are related to Neurocrine Biosciences include NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), bluebird bio (BLUE), Qiagen (QGEN), AveXis (AVXS), BIO-TECHNE (TECH), Ablynx (ABLYF), Spark Therapeutics (ONCE), China Biologic Products (CBPO), Crispr Therapeutics (CRSP), argenx (ARGX), Aerie Pharmaceuticals (AERI), Halozyme Therapeutics (HALO), Regenxbio (RGNX) and Repligen (RGEN).
Who are Neurocrine Biosciences' key executives?
Neurocrine Biosciences' management team includes the folowing people:
- Dr. Kevin C. Gorman, CEO & Director (Age 60)
- Mr. Matthew C. Abernethy, Chief Financial Officer (Age 38)
- Dr. Haig P. Bozigian, Chief Devel. Officer (Age 60)
- Mr. Eric S. Benevich, Chief Commercial Officer (Age 53)
- Dr. Christopher F. O'Brien, Exclusive Consultant (Age 61)
Has Neurocrine Biosciences been receiving favorable news coverage?
News stories about NBIX stock have trended somewhat positive on Monday, according to Accern Sentiment Analysis. Accern scores the sentiment of news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Neurocrine Biosciences earned a news sentiment score of 0.08 on Accern's scale. They also assigned news articles about the company an impact score of 45.95 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
Who are Neurocrine Biosciences' major shareholders?
Neurocrine Biosciences' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.46%), BB Biotech AG (3.79%), Franklin Resources Inc. (2.62%), Artisan Partners Limited Partnership (2.19%), Wells Fargo & Company MN (1.06%) and OppenheimerFunds Inc. (0.93%). Company insiders that own Neurocrine Biosciences stock include Christopher Flint Obrien, Corinne H Nevinny, Darin Lippoldt, Dimitri E Grigoriadis, Eric Benevich, Gary A Lyons, Haig P Bozigian, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Stephen A Sherwin, Timothy P Coughlin and William H Rastetter. View Institutional Ownership Trends for Neurocrine Biosciences.
Which major investors are selling Neurocrine Biosciences stock?
NBIX stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Millennium Management LLC, Neuberger Berman Group LLC, Dupont Capital Management Corp, DekaBank Deutsche Girozentrale, A.R.T. Advisors LLC, BB Biotech AG and Candriam Luxembourg S.C.A.. Company insiders that have sold Neurocrine Biosciences company stock in the last year include Christopher Flint Obrien, Corinne H Nevinny, Darin Lippoldt, Dimitri E Grigoriadis, Eric Benevich, Gary A Lyons, Haig P Bozigian, Kevin Charles Gorman, Kyle Gano, Stephen A Sherwin and William H Rastetter. View Insider Buying and Selling for Neurocrine Biosciences.
Which major investors are buying Neurocrine Biosciences stock?
NBIX stock was bought by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Artisan Partners Limited Partnership, Victory Capital Management Inc., BlackRock Inc., Rock Springs Capital Management LP, Point72 Asset Management L.P., Amundi Pioneer Asset Management Inc. and Columbus Circle Investors. View Insider Buying and Selling for Neurocrine Biosciences.
How do I buy shares of Neurocrine Biosciences?
Shares of NBIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Neurocrine Biosciences' stock price today?
One share of NBIX stock can currently be purchased for approximately $99.07.
How big of a company is Neurocrine Biosciences?
Neurocrine Biosciences has a market capitalization of $9.15 billion and generates $161.63 million in revenue each year. The company earns $-142,540,000.00 in net income (profit) each year or ($1.62) on an earnings per share basis. Neurocrine Biosciences employs 400 workers across the globe.
How can I contact Neurocrine Biosciences?
Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The company can be reached via phone at 858-617-7600 or via email at [email protected]
MarketBeat Community Rating for Neurocrine Biosciences (NBIX)
MarketBeat's community ratings are surveys of what our community members think about Neurocrine Biosciences and other stocks. Vote "Outperform" if you believe NBIX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NBIX will underperform the S&P 500 over the long term. You may vote once every thirty days.
